Evidence map›Paper›PMID 35813938›Full record

ArticleClinical and translational radiation oncology2022

Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment.

Zachary A Seymour, Stephanie Daignault-Newton, P W McLaughlin, Howard Sandler, William Jackson, Skyler B Johnson, David Miller, John Wei, Martin Sanda, Daniel A Hamstra

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Zachary A SeymourBeaumont Health, Department of Radiation Oncology, Dearborn, MI, United States.
Stephanie Daignault-NewtonUniversity of Michigan, Department of Radiation Oncology, Ann Arbor MI, United States.
P W McLaughlinUniversity of Michigan, Department of Radiation Oncology, Ann Arbor MI, United States.
Howard SandlerCedars Sinai Medical Center, Department of Radiation Oncology, Los Angeles, CA, United States.
William JacksonUniversity of Michigan, Department of Radiation Oncology, Ann Arbor MI, United States.
Skyler B JohnsonThe University of Utah, Department of Radiation Oncology, Salt Lake City, UT, United States.
David MillerUniversity of Michigan, Department of Urology, Ann Arbor, MI, United States.
John WeiUniversity of Michigan, Department of Urology, Ann Arbor, MI, United States.
Martin SandaEmory University, Department of Urology, Atlanta, GA, United States.
Daniel A HamstraBaylor College of Medicine, Department of Radiation Oncology, Houston, TX, United States.
University of Michigan–Ann Arbor · USBaylor College of Medicine · USCedars-Sinai Medical Center · USEmory University · USOakland University · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective/purpose: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or Materials/methods: The Expanded Prostate Cancer Index (EPIC) domains were scored with differences evaluated at a median 15.8 years follow up based upon mean EPIC summary domains by ANOVA with pairwise post-hoc comparisons adjusted for age. Patient differences of current survey from first cross-section are reported as median change in summary score for each treatment group at median of 2.2 and 6.0, and 15.8 years. Results: Among men still alive response rate was 52% in BT, 60% in 3D CRT, and 62% in RP resulting in 30, 41, and 330 QOL questionnaires to evaluate for each corresponding modality at median follow up of 15.8 years. Men were a mean 75.3, 83.6, and 79.3 years of age after RP, 3DCRT, and BT, respectively.At a median of 15.8 years, there were largely persistent differences in EPIC domains without substantial evolution in QoL from middle time points. Persistent worsening in urinary irritative and bowel domain with 3DRT or BT compared to RP. Trend towards worse urinary incontinence with RP were noted without statistical differences within radiotherapy options. Conclusion: As the EPIC patient reported outcomes with the longest follow-up, these data uniquely reveal temporal trends from 2 to 15 years post treatment. However, the treatment modalities of open RP, 3D CRT without image guidance or intensity modulation, and BT without peripheral loading or MRI guidance may not reflect modern techniques.

Identifiers

PMID35813938
PMCPMC9256969
OpenAlexW4281670458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.